US › Healthcare

GH Research PLC (GHRS)

US · Healthcare · Biotechnology

$28.72+3.50%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-15.1M

EPS

$-0.23

EPS estimate

$-0.31

EPS came in at -0.23 against a street estimate of -0.31 — a beat of 25.8%.

Key statistics

Market cap

$1.91B

Forward P/E

0.0

P/B

5.18

Book value

$5.24

EPS (TTM)

$-0.99

52-week high

$31.44

52-week low

$12.04

50-day MA

$28.19

200-day MA

$20.17

Beta

1.28

Analyst view

Analysts rate GH Research PLC a strong buy (8 buy, 0 hold, 0 sell out of 8) with an average price target of $42.89.

Shareholding

Insiders

24.20%

Institutions

71.38%

Largest institutional holders

Fund	Stake
Bvf Inc	12.60%
RA Capital Management, LLC	11.18%
RTW INVESTMENTS, LLC	8.64%
FMR Inc	7.48%
Deep Track Capital, LP	4.86%
venBio Select Advisor LLC	2.62%
The Toronto-Dominion Bank	2.04%
Foresite Capital Management VI LLC	1.37%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for GH Research PLC — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.